Patient info Open main menu

Gaviscon Peppermint Tablets 500 – patient leaflet, side effects, dosage

Last updated: · Text from the MHRA, as of · About this document

Medicine status: No longer supplied Details

Medicine strength:
500 mg + 170 mg + 100 mg + 25 mg

Patient leaflet - Gaviscon Peppermint tablets 500

1. What Gaviscon Peppermint Tablets 500 are and what they are used for

Gaviscon Peppermint Tablets 500 belong to a group of medicines called “reflux suppressants”, which form a protective layer on top of the stomach contents to prevent stomach acid escaping from the stomach where it works into the food pipe causing pain and discomfort.

They are used for the treatment of symptoms of gastro-oesophageal reflux such as acid regurgitation, heartburn and indigestion (related to reflux), for example following meals or during pregnancy, and in patients with symptoms related to oesophagitis.

You must talk to a doctor if you do not feel better or if you feel worse after 7 days.

2. What you need to know before you take Gaviscon Peppermint Tablets 500

Do not take if you know that you are allergic to any of the ingredients.

This medicine contains 126.5 mg sodium (main component of cooking/table salt) in each tablet. This is equivalent to 6.3 % of the recommended maximum daily dietary intake of sodium for an adult.

Gaviscon Peppermint Tablets 500 is indicated for short term treatment only unless advised by your healthcare professional. Talk to your pharmacist or doctor if you need Gaviscon Peppermint Tablets 500 on a daily basis for a prolonged period of time or on a regular basis, especially if you have been advised to have a low salt diet.

This medicine contains 7.5 mg aspartame in each tablet.

Aspartame is a source of phenylalanine. It may be harmful if you have phenylketonuria (PKU), a rare genetic disorder in which phenylalanine builds up because the body cannot remove it properly.

If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.

Do not take this product within 2 hours of taking other medicines by mouth as it can interfere with the action of some other medicines.

You can take this product if you are pregnant or breast-feeding.

3. How to take Gaviscon Peppermint Tablets 500

Always take this medicine exactly as described in this leaflet or as your doctor or pharmacist has told you. Check with your rdoctor or pharmacist if you are not sure.

For oral administration. Chew thoroughly before swallowing.

The recommended dose is:

Adults, including the elderly and children 12 years and over: When symptoms occur take one to two tablets after meals and at bedtime.

Children under 12 years: Should only be taken on medical advice.

If you forget to take Gaviscon Peppermint Tablets 500

If you forget a dose, it is not necessary to double the dose next time, just carry on taking as before.

If you take more Gaviscon Peppermint Tablets 500 than you should If you take too much of this product you may feel bloated and experience some abdominal discomfort. It is unlikely to cause you any harm, but please consult your doctor or pharmacist if this doesn’t go away.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Very rare (less than 1 in 10,000) chance of an allergic reaction to the ingredients. Symptoms of this may include skin rash, itching, difficulty breathing, dizziness, or swelling of the face, lips, tongue or throat.

If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: http://www.mhra.gov.uk/yellowcard. By reporting side effects, you can help provide more information on the safety of this medicine.

5. How to store Gaviscon Peppermint Tablets 500

Do not store above 30oC.

Keep out of the sight and reach of children.

Do not use after the expiry date (EXP: month/year) shown.

6. C o n t e n t s o f t h e p a c k a n d o t h e r information

WhatGavisconPeppermintTablets500contain

Each chewable tablet contains 500 mg sodium a lginate, 267 mg sodium hydrogen carbonate and 160 mg calcium carbonate as the active ingredients.

The other ingredients are sodium mannitol (E421), macrogol 20,000, copovidone, aspartame (E951), peppermint flavouring, magnesium stearate and acesulfame potassium.

What Gaviscon Peppermint Tablets 500 looks like and contents of the pack Gaviscon Peppermint Tablets 500 are circular tablets with an off white to cream, slightly mottled appearance.

These tablets do not contain gluten.

Gaviscon Peppermint Tablets 500 are available in pack sizes 12, 20, 24, 40, 60 and 80. Not all pack sizes may be marketed.

Product Licence Holder: Benckiser Healthcare (UK) Limited, Dansom Lane, Hull, HU8 7DS, United Kingdom

Manufacturer: RB NL Brands B.V., Schiphol Boulevard 207, 1118 BH Schiphol, Netherlands

Date of preparation: December 2021.

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PL 00063/0136

Last revision stated in the text: December 2021 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Gaviscon Peppermint tablets 500

Active substances Aluminium hydroxide gel dried, Magnesium trisilicate, Sodium bicarbonate, Alginic acid
Strength 500 mg + 170 mg + 100 mg + 25 mg
Pharmaceutical form Chewable tablet
An off-white to cream, slightly mottled tablet.
How is it taken Oral
Is it available? No, all its packs are listed as discontinued (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Marketing authorisation PL 00063/0136 (first authorised 7 October 2008)
Marketing authorisation holder Reckitt Benckiser Healthcare (UK) Limited Dansom Lane
Codes BNF 01010201

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.1.0 of 12 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.